Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
/in Dendritic Cells, Glioblastoma, International Publications, IOZK VeröffentlichungenConstruction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors
/in International Publications, Newcastle Disease VirusHyperthermia induces cytoskeletal alterations and mitotic catastrophe in p53-deficient H1299 lung cancer cells
/in Hyperthermia, International PublicationsPre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease
/in Dendritic Cells, International Publications, Ovarian CancerMonitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients
/in Dendritic Cells, Glioblastoma, International PublicationsCellular immunotherapy using dendritic cells against multiple myeloma
/in Dendritic Cells, International Publications, Multiple MyelomaRe-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer: a potential modality for inducing long-term survival in selected patients
/in HyperthermiaThe blockade of immune checkpoints in cancer immunotherapy
/in Checkpoint-Inhibitors, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer